硫酸镁联合拉贝洛尔治疗妊娠期高血压患者的临床疗效

Clinical Efficacy of Magnesium Sulfate in Combination with Labetalol in Patients with Hypertension During Pregnancy

目的探究予以妊娠期高血压患者硫酸镁联合拉贝洛尔治疗的临床疗效。方法方便选取2019年6月—2022年10月东台市人民医院收治的216例妊娠期高血压孕妇为研究对象。随机分为对照组与观察组,各108例。对照组行拉贝洛尔治疗,观察组行硫酸镁联合拉贝洛尔治疗。对比两组治疗前后血压、尿蛋白指标、临床疗效以及不良妊娠结局发生情况。结果治疗后,观察组收缩压、舒张压与尿蛋白指标均低于对照组,差异有统计学意义(P<0.05)。观察组临床总有效率(96.30%)高于对照组(80.56%),差异有统计学意义(P<0.05)。观察组不良妊娠结局总发生率(6.48%)低于对照组(21.30%),差异有统计学意义(P<0.05)。结论针对妊娠期高血压孕妇予以硫酸镁联合拉贝洛尔治疗效果优异,更有利于孕妇血压保持在安全水平,提高疗效,减少不良妊娠的发生率。

Objective To investigate the clinical efficacy of magnesium sulfate combined with labetalol in patients with hypertension during pregnancy.Methods A total of 216 pregnant women with gestational hypertension admitted to Dongtai People's Hospital from June 2019 to October 2022 were easily selected as the study subjects.They were randomly divided into control group and observation group,with 108 cases each.The control group was treated with labetalol,and the observation group was treated with magnesium sulfate combined with labetalol.The blood pressure,urine protein indexes,clinical efficacy and adverse pregnancy outcomes of the two groups before and after treatment were compared.Results After treatment,the systolic blood pressure,diastolic blood pressure and urine protein indexes in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The observation group had a higher total clinical effective rate(96.30%)than the control group(80.56%),and the difference was statistically significant(P<0.05).The overall incidence of adverse pregnancy outcomes in the observation group(6.48%)was lower than that in the control group(21.30%),and the difference was statistically significant(P<0.05).Conclusion The treatment effect of magnesium sulfate combined with labetalol for pregnant women with hypertension during pregnancy is excellent,which is more conducive to maintaining the blood pressure of pregnant women at a safe level,improving the efficacy and reducing the probability of adverse pregnancy.